⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MTVA News
MetaVia Inc. Common Stock
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
prnewswire.com
MTVA
Form 8-K
sec.gov
MTVA
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
prnewswire.com
MTVA
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
globenewswire.com
JUNS
DYAI
PHIO
CVKD
TNXP
MTVA
XAIR
AEMD
NSRX
ICU
JAGX
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
prnewswire.com
MTVA
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
prnewswire.com
MTVA
Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream
globenewswire.com
CRGO
OESX
CLNN
UMAC
AEMD
MTVA
ASPI
USAU
ZENA
USEG
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
globenewswire.com
CRGO
OESX
UMAC
CLNN
MTVA
ASPI
AEMD
ZENA
USEG
USAU
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
prnewswire.com
MTVA
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
prnewswire.com
MTVA